Bavarian Nordic’s MVA-BN® Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

KVISTGAARD, Denmark, February 21, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that its MVA-BN vaccine platform technology has been selected by the Defense Threat Reduction Agency (DTRA), a part of the United States Department of Defense, for the development of a vaccine against two potential biological threats to national security - Burkholderia pseudomallei and Burkholderia mallei.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC